Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations

Abstract

An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.

What is claimed is:  
     
       1. A method of inhibiting a fungal infection comprising administering to the skin or a mucous membrane of a mammal in need thereof, an effective amount of a composition comprising a culture supernatant or filtrate of a lactic acid-producing  Bacillus coagulans  bacterium, Emu oil, an a non-microbially derived anti-fungal agent. 
     
     
       2. The method of  claim 1 , wherein said composition is an emulsion, create, lotion, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder, or semi-solid formulation. 
     
     
       3. The method of  claim 1 , wherein the Emu Oil comprises approximately 0.5% to approximately 99.9%, by weight of said composition. 
     
     
       4. The method of  claim 1 , wherein the Emu Oil comprises approximately 10% to approximately 75%, by weight of said composition. 
     
     
       5. The method of  claim 1 , wherein the Emu Oil comprises approximately 25% to approximately 60%, by weight of said composition. 
     
     
       6. The method of  claim 1 , wherein the concentration of the culture supernatant or filtrate ranges from approximately 1% to approximately 90%, by weight of said composition. 
     
     
       7. The method of  claim 1 , wherein the concentration of the culture supernatant or filtrate ranges from approximately 10% to approximately 75%, by weight of said composition. 
     
     
       8. The method of  claim 1 , further comprising one or more compounds selected from a group comprising: dimethyl sulfoxide (DMSO), methylsulfonylmethane (MSM), and Lignisul MSM. 
     
     
       9. The method of  claim 1 , further comprising one or more anti-microbial agents selected from the group consisting of a quartenary ammonium chloride, an iodine or iodifer compound, a phenolic compound, an alcohol compound and an alcohol tincture. 
     
     
       10. The method of  claim 1 , wherein said fungal infection comprises one or more microbes selected from the group consisting of Candida species and Trichophyton species. 
     
     
       11. The method of  claim 1 , wherein said non-microbially derived anti-fungal agent is selected from the group consisting of a Dapsone compound, a Fluconazole compound, a Flucytosine compound, a Griseofulvin compound, an Itraconazole compound, a Ketoconazole compound, a Miconazole KI compound, an Amphotericin B compound, a Carbol-Fuchsin compound, a Ciclopirox compound, a Clotrimazole compound, an Econazole compound, an Haloprogin compound, a Mafenide compound, a Miconazole compound, a Naftifine compound, a Nystatin compound, an Oxiconazole compound, a Silver Sulfadiazine compound, a Sulconazole compound, a Terbinafine compound, a Tioconazole compound, a Tolnafiate compound, an Undecylenic acid compound, a Butoconazole compound, a Terconazole compound, and a Gentian Violet compound. 
     
     
       12. The method of  claim 1 , wherein said non-microbially derived anti-fungal agent is a Miconazole nitrate compound. 
     
     
       13. The method of  claim 1 , wherein said composition further comprises a culture supernatant or filtrate of a  Pseudomonas lindbergii  bacterium.